A Diversified Pipeline
Our pipeline is comprised of first or best-in-class antibody therapeutic candidates for serious respiratory diseases and cancer.
 Program |
Pre- clinical |
Phase I |
Phase I/II |
Phase II |
Patient Screen |
| KB001/001-A (Anti-PcrV of Pseudomonas) | |||||
Pneumonia Prevention |
KB001 | Pseudomonas Colonization | |||
| KB001-A* | |||||
| Cystic Fibrosis | KB001-A | Pseudomonas Infection | |||
| KB004 (Anti-EphA3) | |||||
| Hematalogic Malignancies | KB004 | EphA3 Expression | |||
| KB003 (Anti-GM-CSF) | |||||
| Severe Asthma*** | KB002** | KB003 | Reversibility |
* KB001 precursor for KB001-A. Future studies with KB001-A. Sanofi is conducting a Phase 1 at higher doses than previously studied, and plans to follow this study with pivotal studies in VAP prevention
** KB002 precursor for KB003. Phase 2 and future studies with KB003
*** Based on the results of the Phase 2 study in severe asthma patients, we have discontinued development of KB003 in severe asthma.
Disclaimer: The information contained above concerns biologics that are under pre-clinical and/or clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). They are currently limited by Federal law to investigational use, and no representations are made as to their safety or effectiveness for the purposes for which they are being investigated.
Technology
KaloBios’ patented proprietary Humaneered® technology platform is designed to address problems of antibody engineering.
Learn More